Clinical trials for Sarcoma and GIST

99 currently recruiting clinical trials
Phase 1 / Phase 2 Sarcoma and GIST #NCT02275286 #2024-518199-30-00
Cohorte D
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Systemic Treatment-Naive Chemotherapy
Required soft tissue sarcoma locations
Retroperitoneum
2 recruiting sites
Grupo Espanol de Investigacion en Sarcomas
Phase 1 / Phase 2 Sarcoma and GIST #NCT02275286 #2024-518199-30-00
Cohorte C
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required previous treatments at localized stage
Systemic Treatment-Naive
Required soft tissue sarcoma locations
Retroperitoneum
Excluded previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
2 recruiting sites
Grupo Espanol de Investigacion en Sarcomas
Phase 1 / Phase 2 Sarcoma and GIST #NCT06797999 #2024-516900-41-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Adcendo ApS
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT05614739
Cohortes A1, C1, D1 et D2
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07340190
Bras B
Required disease stage
Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Novartis
Phase 1 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07340190
Bras A
Required disease stage
Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Novartis
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT04913285
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Surgery Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Surgery Radiotherapy
1 recruiting site
Laboratoires Pierre Fabre
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT05176483 #2023-510061-10-00
Cohortes d’escalade de dose
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Exélixis
Phase 1 Breast cancer Lung cancer Pancreas cancer Lymphoma CLL & Richter's syndrome Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST #NCT06823167 #2025-523160-20-00
Partie A
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Mesothelium B cell lymphoma Richter's syndrome Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Soft tissue sarcoma
Required histologic sub types
Non-squamous NSCLC Large B cell lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma Lymphocytic lymphoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Immunome, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05307705 #2022-000175-40
Phase 1A
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie